## Abstract Thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications in the myelodysplastic syndromes (MDS). Reliable data regarding the frequency and consequences of thrombocytopenia in MDS are lacking. An extensive literature review indicated that the prevalence of thromb
Clustering in the incidence of myelodysplastic syndromes
โ Scribed by Xiaomei Ma; Steve Selvin; Azra Raza; Kathryn Foti; Susan T. Mayne
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 668 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
โฆ Synopsis
The myelodysplastic syndromes (MDS) are a group of malignancies with poor prognosis and obscure etiology. To better understand the distribution of MDS in the population and help generate etiologic hypotheses, we assessed potential clustering in the incidence of MDS in the state of Connecticut using population-based cancer registry data that recently became available. A significant spatial clustering was identified. The most likely area with a high incidence of MDS included 46 census tracts near the west border of Connecticut, and the ratio of observed/expected cases was 2.84. The P value associated with this cluster was 0.0001. Although no temporal clustering was indicated, a space-time analysis identified a cluster in the central south of Connecticut from March 2002 through August 2003 (P=0.008). This is the first analysis of potential clustering in the incidence of MDS using population-based data. If the intriguing finding on spatial clustering is supported by future studies with larger sample sizes and/or in other geographic areas, it would be extremely interesting to explore the "causes" of clustering, which may help shed light on the etiology of MDS.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND. Myelodysplastic syndromes (MDS) became reportable to the Surveillance, Epidemiology, and End Results (SEER) Program (the United States cancer surveillance program) in 2001. This provided the first opportunity to examine the incidence and survival of patients with MDS in
T he article by Ferrara et al. 1 in this issue of Cancer describes the treatment of patients with poor prognosis myelodysplastic syndromes (MDS) using intensive remission induction chemotherapy followed by peripheral blood stem cell transplantation for patients age ฯฝ 60 years. Thirty-two patients wi
Anaemia is prevalent in patients with myelodysplastic syndromes (MDS), and most patients with MDS receive regular red blood cell transfusions, which can lead to iron overload. Some patients may already have iron overload before transfusions begin, as a result of ineffective erythropoiesis. Iron over